Quick answer: Zepbound (tirzepatide) was approved by the FDA for sleep apnea on December 20, 2024, for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It was the first medicine approved for this condition.[1] In the SURMOUNT-OSA trials, Zepbound sleep apnea treatment cut breathing interruptions by 25 to 29 events per hour over a year, versus about 5 with placebo.[2] Because OSA is a medical use beyond weight loss, Medicare Part D plans can cover it.[4]
This guide covers the approval, the trial results, dosing and what it means for coverage. For the drug itself, see our tirzepatide profile.
What the FDA approved
- Date: December 20, 2024.[1]
- Who: adults with obesity and moderate to severe OSA, used with a reduced-calorie diet and more physical activity.[1][3]
- Basis: two randomized, double-blind, placebo-controlled trials of 469 adults without type 2 diabetes.[1]
- Review status: the FDA gave the application Fast Track, Priority Review and Breakthrough Therapy designations.[1]
- How it works: the FDA said the improvement in breathing is likely related to weight loss.[1]
Zepbound’s other approved use is weight reduction and long-term maintenance.[3] Mounjaro, the same drug sold for type 2 diabetes, does not carry the sleep apnea indication.[6] See Zepbound vs Mounjaro.
What is obstructive sleep apnea?
In OSA, the airway repeatedly narrows or closes during sleep, causing pauses or shallow breathing. Severity is measured with the apnea-hypopnea index (AHI), the number of breathing pauses or shallow breaths per hour of sleep. Moderate OSA is an AHI of 15 to 29, and severe is 30 or more. The FDA notes that OSA is more common in people with overweight or obesity.[1]
Who is a candidate for Zepbound for sleep apnea?
Based on the approved indication and the trials, the treatment is aimed at:[1][3]
- Adults, not children.
- People with obesity, not people with sleep apnea at a lower weight.
- Moderate to severe OSA, usually confirmed by a sleep study.
- People who can follow a reduced-calorie diet and increase activity alongside the drug.
It is not suitable for people with a personal or family history of medullary thyroid cancer or MEN 2, or a prior serious allergic reaction to tirzepatide.[1]
SURMOUNT-OSA trial results
The two trials enrolled adults with moderate to severe OSA and obesity. Trial 1 included people who could not or would not use positive airway pressure (PAP, such as CPAP). Trial 2 included people already using PAP, who stopped it for a week before each sleep test.[2][3] Participants took their highest tolerated dose, 10 or 15 mg weekly, for 52 weeks.[1]
| Week 52 result | Trial 1 (no PAP) | Trial 2 (on PAP) |
|---|---|---|
| Starting AHI (events per hour) | 51.5[2] | 49.5[2] |
| AHI change, Zepbound | −25.3[2] | −29.3[2] |
| AHI change, placebo | −5.3[2] | −5.5[2] |
| AHI percent change, Zepbound vs placebo | −50.7% vs −3%[3] | −58.7% vs −2.5%[3] |
| Body weight change, Zepbound vs placebo | −17.7% vs −1.6%[3] | −19.6% vs −2.3%[3] |
| Remission or mild OSA without symptoms | 42.2% vs 15.9%[3] | 50.2% vs 14.3%[3] |
Tirzepatide also improved oxygen levels during sleep (hypoxic burden), a marker of inflammation (hsCRP), systolic blood pressure and sleep-related quality of life, compared with placebo.[2]
Dosing for sleep apnea
The starting schedule is the same as for weight loss: 2.5 mg weekly for 4 weeks, then increases of 2.5 mg no sooner than every 4 weeks.[3] The difference is the maintenance dose:
Side effects in the sleep apnea trials were similar to those in the weight-loss trials, mostly mild to moderate nausea, diarrhea, vomiting and constipation.[2][3] See the full tirzepatide dosage chart.
Medicare Part D coverage implications
Medicare Part D generally does not cover drugs used only for weight loss. The OSA approval changed that for Zepbound in one situation: when it is prescribed for moderate to severe OSA.
- OSA is a Part D-covered use. CMS lists moderate to severe OSA, along with type 2 diabetes and certain liver disease, as conditions for which GLP-1 drugs are covered through Part D plans.[4]
- Plans still decide. Each Part D or Medicare Advantage drug plan sets its own formulary, cost-sharing and prior authorization rules. Expect to need a sleep study documenting moderate to severe OSA and a record of obesity.
- Not part of the GLP-1 Bridge. Since July 1, 2026, Medicare has run a temporary GLP-1 Bridge for weight management with a $50 monthly copay. People with moderate to severe OSA are not eligible for it and should get their GLP-1 through their regular Part D plan.[4][5]
- Bridge formats differ. The Bridge covers only the Zepbound KwikPen for weight management, not the single-dose pen or vial.[4] Formats covered for OSA depend on your Part D plan’s formulary.
To check your own coverage, look up Zepbound in your plan’s formulary, look for prior authorization notes, or call the number on your member card. Our Medicare and Zepbound guide covers this in more depth.
Commercial insurance and Medicaid
Coverage for sleep apnea varies by plan. Some employer and individual plans that exclude weight-loss drugs may cover Zepbound when it is prescribed for OSA, often with prior authorization. Medicaid coverage depends on the state. If your plan denies coverage, ask your prescriber whether an appeal citing the OSA indication is appropriate.
Zepbound and CPAP
Zepbound is approved alongside a reduced-calorie diet and exercise.[3] One of the two trials included people who stayed on PAP, and the FDA described Zepbound as a drug treatment option without calling it a replacement for PAP.[1] Any change to CPAP use should be guided by a sleep specialist, ideally with a follow-up sleep study.
For how fast the weight effect builds, see how long does tirzepatide take to work.
